Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $170.33 Analyst target: $165.31 Upside: -2.95%
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
See the full interactive analysis & chart →Informational only — not investment advice.